Sun Pharma Advanced Research Company Ltd's Q4FY25 Quarter Results
- 20 May 2025
Result Summary
- Sun Pharma Advanced Research Company Ltd reported a 38.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were up by 33.7% QoQ and - - YoY.
- The net profit increased 33.1% QoQ and - - YoY.
- The earnings per share (EPS) of Sun Pharma Advanced Research Company Ltd declined at 3.3 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 20.96 | 15.10 | 0.00 | 38.8% | - |
Total Expenses | 126.37 | 94.54 | 0.00 | 33.7% | - |
Profit Before Tax | -105.41 | -79.44 | - | 32.7% | NaN% |
Tax | 0.38 | 0.07 | 0.00 | 442.9% | - |
Profit After Tax | -105.79 | -79.51 | 0.00 | 33.1% | - |
Earnings Per Share | -3.30 | -2.50 | 0.00 | 32.0% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Sun Pharma Advanced Research Company Ltd (SPARC) is a research-driven biopharmaceutical company that primarily focuses on developing innovative pharmaceutical products. As a subsidiary of Sun Pharmaceutical Industries Ltd, SPARC specializes in drug discovery and research, aiming to address unmet medical needs in the fields of oncology, neurodegenerative disorders, and inflammation. The company has been involved in developing novel drug delivery systems and has a robust pipeline of products in various stages of development. The company is part of the broader pharmaceutical industry, which is characterized by rapid advancements in drug development and stringent regulatory environments. Recent major developments, if any, specific to SPARC are not available in the provided data.
Revenue
In the fourth quarter of the fiscal year 2025 (Q4FY25), Sun Pharma Advanced Research Company Ltd reported a total income of ₹20.96 crores. This represents a significant quarter-over-quarter (QoQ) increase of 38.8% compared to ₹15.10 crores in the third quarter of FY25 (Q3FY25). The data for the fourth quarter of the previous fiscal year (Q4FY24) is not available, making it impossible to calculate the year-over-year (YoY) change in total income. The increase in revenue on a QoQ basis suggests an upward trajectory in income generation for this quarter.
Profitability
The company recorded a profit before tax (PBT) of -₹105.41 crores in Q4FY25, compared to -₹79.44 crores in Q3FY25, indicating a QoQ decrease in profitability by 32.7%. The profit after tax (PAT) for Q4FY25 stood at -₹105.79 crores, also reflecting a QoQ decline of 33.1% from the previous quarter's -₹79.51 crores. Earnings per share (EPS) were reported at -₹3.30 in Q4FY25, compared to -₹2.50 in Q3FY25, marking a decrease of 32.0% QoQ. The tax paid during Q4FY25 was ₹0.38 crores, which shows a substantial increase of 442.9% from Q3FY25. There is no YoY data available to analyze changes over the past year.
Operating Metrics
During Q4FY25, the company reported total expenses of ₹126.37 crores, reflecting a 33.7% increase from the ₹94.54 crores reported in Q3FY25. The data shows an upward trend in operating expenses on a QoQ basis, which may impact the company's overall operating efficiency. Key financial ratios such as the P/E ratio, debt-to-equity ratio, and current ratio cannot be calculated with the available data as it lacks specific information on equity, liabilities, and market valuation. The data provided does not include specific trends or anomalies related to operational efficiency or productivity metrics beyond the financial figures.